Literature DB >> 35347005

The Trend of Combined Modality Treatment and its Outcomes in Elderly Patients With Primary CNS Lymphoma: A 12-year Population-based Analysis Using Propensity Score.

Yazan Samhouri1, Moaath K Mustafa Ali2, Cyrus Khan3, Rodney Wegner4, Seung Tae Lee2, John Lister3.   

Abstract

BACKGROUND/AIM: The addition of radiation to chemotherapy in elderly patients with primary central nervous system lymphoma (PCNSL) remains controversial. This aim of this study was to assess the trend of combined modality treatment (CMT) and compare its survival with chemotherapy alone and radiation alone in non-HIV patients. PATIENTS AND METHODS: We identified 6,537 patients who received single treatment modality, CMT, or no treatment at all between 2004 and 2015 from the National Cancer Database. Factors affecting treatment selection were investigated using a logistic regression model. Annual percentage change (APC) was calculated to assess the trend of CMT use. A propensity score weighting methodology was used to compare survival outcomes.
RESULTS: Only 12.8% of patients received CMT, and this proportion steadily declined between 2004 (17.7%) and 2015 (8.7%), with an APC of -6.0% (95%CI=-8.0 - -4.0, p-value <0.001) during the 12 years. Apart from classical prognostic factors (age and comorbidities), treatment selection was significantly influenced by sex, facility type, degree of urbanization, and type of insurance. CMT had improved survival [median overall survival 19.5 months (95%CI=15.7-22.8)] compared with single-modality treatment. This effect was more prominent in the first year.
CONCLUSION: Socioeconomic factors affect the selection of treatment in elderly patients with PCNSL. CMT is falling out of favor in this patient population due to the risks of neurotoxicity. Further work should focus on developing strategies that minimize toxicity and access disparities without compromising survival.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  CMT; PCNSL; chemotherapy; elderly; radiation

Mesh:

Year:  2022        PMID: 35347005     DOI: 10.21873/anticanres.15663

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Changes in survival over time for primary brain and other CNS tumors in the United States, 2004-2017.

Authors:  Gino Cioffi; Kristin A Waite; Jacob L Edelson; Carol Kruchko; Quinn T Ostrom; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2022-10-05       Impact factor: 4.506

2.  Socioeconomic deprivation and survival outcomes in primary central nervous system lymphomas.

Authors:  Xiangyang Deng; Xionggang Yang; Chunlei Yang; Kezhu Chen; Junwei Ren; Jun Zeng; Quan Zhang; Tianwen Li; Qisheng Tang; Jianhong Zhu
Journal:  Front Oncol       Date:  2022-08-26       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.